The butyrylcholinesterase K variant and susceptibility to Alzheimer's disease.

Butyrylcholinesterase-knockout reduces brain deposition of fibrillar β-amyloid in an Alzheimer mouse model

“…Investigations of this BCHE variant have observed that its presence pre-empts progression of AD (Sandbrink et al, 1998;O'Brien et al, 2003). However, other studies have suggested that this variant is associated with AD (Tilley et al, 1999;Wiebusch et al, 1999;Lehmann et al, 2000;Lehmann et al, 2001;McIlroy et al, 2000) and still others have observed no association of BCHE-K variant with AD (Hiltunen et al, 1998;Kehoe et al, 1998;Singleton et al, 1998;Grubber et al, 1999;Ki et al, 1999;Yamamoto et al, 1999). This suggests that the role(s) of BChE in AD may involve other components of the disease and requires further scrutiny.…”

Association of butyrylcholinesterase K variant with cholinesterase-positive neuritic plaques in the temporal cortex in late-onset Alzheimer's disease

“…McIlroy et al 2000;Sandbrink et al 1998;Tilley et al 1999;Wiebusch et al 1999), but not by others (e.g. Brindle et al 1998;Grubber et al 1999;Hiltunen et al 1998;Kehoe et al 1998;Ki et al 1999;Singleton et al 1998;Yamamoto et al 1999). These contrasting results may be partly explained by the relatively young age of some cohorts; our finding is unlikely to be replicated in cohorts with very few APOEε4 carriers aged >75 years.…”

Effect of apolipoprotein E and butyrylcholinesterase genotypes on cognitive response to cholinesterase inhibitor treatment at different stages of Alzheimer's disease

“…[36][37][38] Other investigators found no association. [39][40][41] Some groups have reported a protective effect of BCHE-K genotype on the risk of AD. [42][43][44] A meta-analysis of all published association studies indicates that BCHE-K does not influence the risk of AD (odds ratio (OR) 1.08, 95% confidence interval (CI) 0.96-1.22) (http://www.alzgene.…”